ライフサイエンスコーパス: cystatin

1 fibres, with examples including serpins and cystatins.

2 interaction with statherins/P-B peptide and cystatins.

3 Two proteins, cystatin 1 and myeloblastin, the former of which protect

4 le protein with tetratricopeptide repeats 1, cystatin 1, and interferon-inducible protein with tetrat

5 tion is incompatible with previous models of cystatin amyloid fibrils where the beta-sheet is assumed

6 including Tenascins, Cathepsin-B precursor, cystatin, and numerous Variant-specific Surface Proteins

7 ion, and intracellular content of all type 2 cystatins as well as expression and activity of their po

8 and three were successfully verified, namely cystatin B (CSTB), triosephosphate isomerase (TPI1), and

9 y form of cerebral amyloid angiopathy whilst cystatin B aggregates are found in cases of Unverricht-L

10 Here we apply limited proteolysis to cystatin B amyloid fibrils and show that not only the al

11 Previous work on cystatin B amyloid fibrils revealed that the alpha-helic

12 Cystatin B deletion in TgCRND8 significantly reduces the

13 We show that decreased expression of cystatin B in patient fibroblasts enhances cathepsin act

14 of lipid accumulation in TgCRND8 by removing cystatin B inhibition on lysosomal proteases suggests th

15 with available data for amyloids from either cystatin B or cystatin C.

16 m ROS was attenuated in an NPC cell model by cystatin B over-expression or pharmacological inhibition

17 Cystatin B was recently identified as an acid-resistant

18 Stefin B (cystatin B) is an endogenous cysteine cathepsin inhibito

19 B5 (serine protease inhibitor B5), and CSTB (cystatin B).

20 ied the effects of diminishing expression of cystatin B, an endogenous inhibitor of cathepsins B, H a

21 5 of 266 evaluable proteins (angiopoietin 1, cystatin B, the latency-associated peptide of transformi

22 eletion of the lysosomal protease inhibitor, cystatin B.

23 ed to the cytosol, where the CTSB inhibitors cystatin-B/C were abundantly present.

24 at least partially parallel, arrangement for cystatin beta-sheet structure in mature amyloids and pro

25 y C-reactive protein greater than 3.0 mg/dL, cystatin C >/=1.11 mg/dL, estimated glomerular filtratio

26 lomerular filtration rate, or an increase in cystatin C >=0.3 mg/L from baseline to 180-days.

27 tin vs placebo; P = .033) and decreased mean cystatin C (-0.034 mg/L vs 0.010 mg/L; P = .008).

28 rs911119 was associated with decreased serum cystatin C (6.13% per allele; 95% CI: 5.75 to 6.50; p =

29 l relative risk for CVD of 1.00 per doubling cystatin C (95% CI: 0.82 to 1.22; p = 0.994), which was

30 alysis, we examined the relationship between cystatin C (a marker of renal function) and PASP and pot

31 igher than SCr (AUC-ROC=0.73) and similar to cystatin C (AUC-ROC=0.91).

32 We investigated whether cystatin C (CysC) and neutrophil gelatinase-associated l

33 tion rate (GFR) equations incorporating both cystatin C (CysC) and serum creatinine (Creat) in living

34 Cr is a commonly accepted clinical standard, cystatin C (CysC) has shown superiority in assessment of

35 Cystatin C (CysC) is a better glomerular filtration rate

36 Cystatin C (CysC) is a versatile and ubiquitously-expres

37 Cystatin C (CysC) is an early biomarker of renal dysfunc

38 Cystatin C (CysC) is implicated in neuroprotection and r

39 Of note, circulating cystatin C (CysC) levels were increased in UniNx compare

40 ent redox activity mediated by ferrocene for Cystatin C (CysC), an early kidney failure biomarker, is

41 ating fragments but is potently inhibited by cystatin C (CysC).

42 Serum cystatin C (CysC; subdistribution hazard ratio [SHR], 1.

43 ed GFR estimated from creatinine (eGFR(Cr)), cystatin C (eGFR(Cys)), or both (eGFR(Cr+Cys)) with ioth

44 ion rate estimated from serum creatinine and cystatin C (eGFR) from baseline to year 5.

45 e Epidemiology Collaboration eGFR creatinine-cystatin C (eGFRcreat-cys) equation.

46 eGFR by cystatin C (eGFRcys) and albumin-to-creatinine ratio wer

47 eGFR was calculated using serum creatinine, cystatin C (eGFRcys) and creatinine-cystatin C.

48 GFR should be calculated and reported using cystatin C (eGFRcys) and serum creatinine (eGFRcr-cys) o

49 d GFR estimated from creatinine (eGFRcreat), cystatin C (eGFRcys), and both (eGFRcreat-cys) at baseli

50 dominant disorder in which a variant form of cystatin C (L68Q) readily forms amyloid deposits in cere

51 imilarly, both in patients with high and low cystatin C (median cut-off), higher plasma NGAL levels w

52 le risk prediction model, eGFR (P=0.616) and cystatin C (P=0.937) were no longer associated with mort

53 8.30-21.2); Pnoninferiority = 0.0011], serum cystatin C (Pnoninferiority < 0.0001), serum creatinine

54 n decline of eGFR (Ptrend<0.001) and rise of cystatin C (Ptrend=0.01) and creatinine (Ptrend<0.001) l

55 ive protein -0.0363 (95% CI 0.0601--0.0124), cystatin C -0.0391 (95% CI -0.0772--0.00107).

56 bining a functional damage biomarker (plasma cystatin C [pCysC]) with a tubular damage biomarker (uri

57 All cells internalized cystatin C added to culture media, leading to increased

58 The use of cystatin C alone or in combination with creatinine stren

59 ptide]), there was a significant increase in cystatin C among patients randomized to liraglutide rais

60 e offspring, suggesting the presence of L68Q cystatin C amyloid affected sperm function.

61 Hereditary cystatin C amyloid angiopathy is an autosomal dominant d

62 L68Q protein deposits in human cystatin C amyloid angiopathy patients have also been fo

63 In hereditary cystatin C amyloid angiopathy, a cystatin C variant is d

64 d causes a fatal amyloid disease, hereditary cystatin C amyloid angiopathy.

65 howed increased levels and distinct forms of cystatin C amyloid that were not present in WT mice.

66 Cystatin C amyloids cause a hereditary form of cerebral

67 L68Q epididymal fluid that was depleted of cystatin C amyloids, however, did not impair the motilit

68 cohorts (n = 76,481) with 37,126 measures of cystatin C and added genetic data from 43 studies (n = 2

69 ult ICU survivors, we compared ICU discharge cystatin C and creatinine and their association with 1-y

70 During ICU admission, serum cystatin C and creatinine diverged, so that by ICU disch

71 d to determine the association between serum cystatin C and mortality.

72 espectively, of the indirect effects between cystatin C and PASP.

73 Rosuvastatin 10 mg daily reduces plasma cystatin C and slows kidney function decline in HIV-infe

74 Here we aimed to investigate if uptake of cystatin C and the related inhibitor cystatin E/M occur

75 Conversely, lower creatinine relative to cystatin C appeared to confer adverse prognosis, confoun

76 herapeutics targeted at lowering circulating cystatin C are unlikely to be effective in preventing CV

77 implications for the diagnostic use of serum cystatin C as a marker of kidney function during inflamm

78 Whilst there is good evidence for cystatin C being a marker of GFR and risk in people with

79 red childhood kidney volumes, creatinine and cystatin C blood levels, microalbuminuria, BP, and eGFR.

80 Statins may improve cystatin C by improving glomerular function or by decrea

81 m2, calculated using the combined creatinine-cystatin C CKD-Epidemiology Collaboration Equation.

82 ss than 60 mL/min/1.73 m when estimated from cystatin C compared with glomerular filtration rate esti

83 baseline and 0- to 24-week changes in plasma cystatin C concentration with measures of vascular disea

84 Cystatin C concentrations remained normal in both groups

85 Cystatin C concentrations were associated with CVD risk

86 ation rate (eGFR) using serum creatinine and cystatin C concentrations, and microalbuminuria using ur

87 In contrast to creatinine, cystatin C consistently associated with long-term mortal

88 Within the statin group, changes in cystatin C correlated with changes in endothelial activa

89 e intracellular concentration of ROS inhibit cystatin C dimerization.

90 These could be used to selectively remove cystatin C dimers from biological fluids containing both

91 es/mL was associated with a lower creatinine/cystatin C eGFR at 2 years post-HCT.

92 es/mL was associated with a lower creatinine/cystatin C eGFR two years post-HCT.

93 diagnostic performance of CKD-EPI creatinine-cystatin C equation (2012) in patients with cirrhosis wa

94 Performance of the new CKD-EPI creatinine-cystatin C equation (2012) was superior to previous crea

95 Accuracy of CKD-EPI creatinine-cystatin C equation as quantified by root mean squared e

96 ubjects, GFR estimated by CKD-EPI creatinine-cystatin C equation differed from the mGFR by more than

97 te the performance of the CKD-EPI creatinine-cystatin C equation in subjects with cirrhosis, we compa

98 and "accuracy" of the new CKD-EPI creatinine-cystatin C equation to that of 24-hour urinary creatinin

99 Cystatin C forms non-inhibitory dimers and aggregates by

100 Furthermore, immunodepletion of cystatin C from the conditioned medium completely remove

101 Serum cystatin C has an important role in enhancing accuracy o

102 from serum concentrations of creatinine and cystatin C has been refined using cross-sectional data f

103 ne the extent to which the addition of serum cystatin C improves glomerular filtration rate (GFR) est

104 vation and inflammation were associated with cystatin C in a multivariable model independent of creat

105 Cystatin C in combination with [TIMP-2] x [IGFBP7] 24 ho

106 l variable to investigate the causal role of cystatin C in CVD, including coronary heart disease, isc

107 on analyses did not support a causal role of cystatin C in the etiology of CVD.

108 cell types synthesize monomeric and dimeric cystatin C in vivo, but only secrete monomer.

109 ile serum creatinine fell at 12 hours, serum cystatin C increased, suggestive of decreased creatinine

110 iological studies show that high circulating cystatin C is associated with risk of cardiovascular dis

111 ndelian randomization to investigate whether cystatin C is causally related to CVD in the general pop

112 The cysteine protease inhibitor cystatin C is internalized by some cancer cells, which a

113 Low extracellular cystatin C is linked to pathologic protease activity in

114 The cysteine protease inhibitor cystatin C is thought to be secreted by most cells and e

115 he extracellular concentration of inhibitory cystatin C is thus partly dependent on the abundance of

116 714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18

117 618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.

118 ely associated with childhood creatinine and cystatin C levels (all P values <0.05), but did not asso

119 re media, leading to increased intracellular cystatin C levels by 120-200%.

120 ells are major contributors to extracellular cystatin C levels in healthy mice.

121 filtration rate (GFR) was estimated based on cystatin C levels using the relevant equation.

122 ated on the basis of creatinine (eGFRcr) and cystatin C levels were assessed in </=1735 participants

123 gression models showed that age and baseline cystatin C levels were associated with WRF.

124 Cystatin C levels were positively and plasma high-densit

125 After adjustment for both creatinine and cystatin C levels, higher discharge creatinine was then

126 ut cirrhosis using both serum creatinine and cystatin C levels.

127 munodeficiency virus (HIV) infection, plasma cystatin C may be influenced by factors other than glome

128 C, and elution from columns with immobilized cystatin C oligomers, oligomer-specific antibodies were

129 .002), and GFR-estimating equations based on cystatin C only.

130 In addition, cystatin C participated in the control of extracellular

131 ons, little is known about the regulation of cystatin C production, dimerization, and secretion.

132 of cystatin C under the control of the mouse cystatin C promoter were unable to generate offspring, s

133 mo Diet and Cancer study (MDC) into baseline cystatin C quintiles (n=4757).

134 ation coefficient, serum creatinine-to-serum cystatin C ratio was found to be the best performer in t

135 ient increase in serum creatinine, but serum cystatin C remained stable.

136 combination of newly tested biomarkers with cystatin C resulted in a significantly improved diagnost

137 t this effect is mediated via an increase in cystatin C secretion.

138 ss or diet), or interference with the assay, cystatin C should be measured and estimated GFR should b

139 ciated with mortality when assessed by serum cystatin C than by creatinine.

140 , these results suggest that the addition of cystatin C to creatinine to estimate GFR may improve ide

141 Adding the measurement of cystatin C to that of serum creatinine to determine the

142 L68Q) that express the human L68Q variant of cystatin C under the control of the mouse cystatin C pro

143 hereditary cystatin C amyloid angiopathy, a cystatin C variant is deposited in arterial walls and ca

144 Cystatin C warrants further investigation as a more mean

145 99 to -0.28); the equivalent association for cystatin C was -0.60 kg (95% CI, -0.94 to -0.25) and for

146 ne eGFR was 54+/-20 mL/min per 1.73 m2, mean cystatin C was 11.2 (7.7-16.2) mg/L, and median plasma N

147 Concurrent serum cystatin C was assayed in banked serum samples.

148 Baseline cystatin C was associated with higher carotid intima-med

149 Log cystatin C was directly associated with PASP (adjusted b

150 In contrast, the cysteine protease inhibitor cystatin C was expressed only in tubules.

151 ysis adjusted for age, sex, and comorbidity, cystatin C was near-linearly associated with increased m

152 A causal effect of cystatin C was not detected for any individual component

153 Although mRNA expression of cystatin C was stable, its secretion, which was inhibite

154 legumain inhibitors, cystatin C, E/M, and F, cystatin C was the one mainly produced.

155 ge glomerular filtration rate estimated from cystatin C well matched follow-up chronic kidney disease

156 mated glomerular filtration rate (eGFR), and cystatin C were assessed in 562 patients with heart fail

157 ng; urinary albumin-to-creatinine ratio; and cystatin C were evaluated at study baseline.

158 Several variants of cystatin C were identified and quantified, while none we

159 kidney disease and when both creatinine and cystatin C were used to calculate the eGFR.

160 ration equation, the eGFR was estimated from cystatin C with all available samples per participant ex

161 extent comparable with the W106F variant of cystatin C with optimal uptake properties and resulting

162 Reductions in cystatin C with statin therapy correlate with reductions

163 ssociations of eGFR (based on creatinine and cystatin C) and ACR with cancer risk using Cox regressio

164 L9G,V10G)-, (R8G,L9G,V10G,W106G)-, and W106G-cystatin C) were internalized to a very low extent compa

165 NT-proBNP and IL-6 (but not cystatin C) were more strongly associated with the outco

166 ment (R(2) = 0.989 for CRP; R(2) = 0.939 for cystatin C).

167 markers of filtration (serum creatinine and cystatin C).

168 l, 0.8-4.1] per standard deviation change in cystatin C).

169 ct to limits of detection (CRP, 0.10 mug/mL; cystatin C, 0.003 mug/mL) and coefficients of variation

170 nd coefficients of variation (CRP, 2.4-7.0%; cystatin C, 3.0-8.9%).

171 al serum potassium levels and measurement of cystatin C, a non-creatinine measure of kidney function.

172 ning isogenic cells homozygous for variant B cystatin C, a recessive risk factor for age-related macu

173 od gas, inflammatory cytokine concentration, cystatin C, and alanine aminotransferase.

174 immunosorption, using immobilized monomeric cystatin C, and elution from columns with immobilized cy

175 Four markers (albumin, beta-2-microglobulin, cystatin C, and osteopontin) were undetectable in most A

176 isease Epidemiology Collaboration creatinine-cystatin C, and urate and high-sensitivity C-reactive pr

177 with increased aortic pulsed wave velocity, cystatin C, and urinary albumin-to-creatinine ratio.

178 fication improvement with the measurement of cystatin C, as compared with creatinine, was 0.23 (95% c

179 FR to a higher value with the measurement of cystatin C, as compared with creatinine, was associated

180 nt variable for kidney function (creatinine, cystatin C, beta2-microglobulin).

181 Serum cystatin C, by itself or as a part of an estimated GFR,

182 s, and of the potential legumain inhibitors, cystatin C, E/M, and F, cystatin C was the one mainly pr

183 of GFR-estimating equations with and without cystatin C, including the modification of diet in renal

184 Relationships between cystatin C, kidney function, and cardiovascular risk in

185 allel with Elmo1, as do the plasma levels of cystatin C, lipid peroxides, and TGFbeta1, and erythrocy

186 ed GFR, the formula with both creatinine and cystatin C, namely, CKD-epidemiology cr-cys, outperforme

187 between logged and standardized measures of cystatin C, NT-proBNP (N-terminal pro-B-type natriuretic

188 Cystatin C, NT-proBNP, and IL-6 (but not E-selectin) wer

189 lternative biomarkers (haematocrit, cTnI-hs, cystatin C, or creatinine clearance) also outperformed t

190 not increase albuminuria, proteinuria, serum cystatin C, or serum creatinine levels in TxNIP(-/-) mic

191 plasma biomarkers of renal injury including Cystatin C, Osteopontin, Tissue Inhibitor of Metalloprot

192 ly by iothalamate and creatinine (eGFRcr) or cystatin C, respectively.

193 renal function, C-reactive protein (CRP) and cystatin C, respectively.

194 ith increases in endothelin-1 and creatinine/cystatin C, respectively.

195 Two variants, W106F- and K75A-cystatin C, showed that the internalization can be posit

196 ation, we use redox experiments of monomeric cystatin C, stabilized against domain swapping by an int

197 atients had lower levels of cardiotrophin-1, cystatin C, syndecan-4, and N terminal-probrain natriure

198 inar-specific markers-namely, alpha-amylase, cystatin C, TMEM16A, and NKCC1.

199 neutrophil gelatinase-associated lipocalin, cystatin C, trefoil factor 3, tissue inhibitor of metall

200 eded in a number of assays, such as that for cystatin C, where a 1.5-fold increase in concentration m

201 id not provide evidence for a causal role of cystatin C, with a causal relative risk for CVD of 1.00

202 terminal pro-B-type natriuretic peptide, and cystatin C, with longer QRS interval, with lower heart r

203 accuracy and lowest error were observed with cystatin C-based chronic kidney disease epidemiology col

204 mination of renal function by creatinine and cystatin C-based eGFR revealed decreasing eGFRs in the d

205 (2) of body-surface area was higher with the cystatin C-based eGFR than with the creatinine-based eGF

206 s were consistent for creatinine-based eGFR, cystatin C-based eGFR, and UACR.

207 tly associated with childhood kidney volume, cystatin C-based eGFR, or the risk of microalbuminuria.

208 Kidney function was measured by cystatin C-based estimated glomerular filtration rate (e

209 Creatinine- but not cystatin C-based estimations largely derived over ICU st

210 One of 3 CKD stages diagnosed by cystatin c-based formulas was incorrect, with both overe

211 We compared 51 creatinine-based and/or cystatin c-based formulas with a gold standard (iohexol

212 e-based formulas: approximately 0.70 and for cystatin c-based formulas: approximately 0.85).

213 012) was superior to previous creatinine- or cystatin C-based GFR equations.

214 , and previously reported creatinine- and/or cystatin C-based GFR-estimating equations.

215 lable creatinine at baseline (n=17 951), and cystatin C-based glomerular filtration rate was estimate

216 our knowledge, no previous studies have used cystatin C-based measures of the estimated glomerular fi

217 lomerular filtration rate with creatinine or cystatin C-based standard and kinetic equations as well

218 0% (creatinine-based) and approximately 50% (cystatin c-based), indicating that 90% of the estimation

219 1 promotes fibrosis by driving the effective cystatin C-dependent inhibition of extracellular matrix-

220 ) in young and middle-aged adults who have a cystatin C-derived estimated glomerular filtration rate

221 D) in children, such as creatinine level and cystatin C-derived estimated glomerular filtration rate

222 equation based on both plasma creatinine and cystatin C.

223 are never labelled with anti-TDP-43 or anti-cystatin C.

224 on rate (eGFR) based on serum creatinine and cystatin C.

225 explaining 2.8% of the observed variation in cystatin C.

226 data for amyloids from either cystatin B or cystatin C.

227 rer prognosis within cohorts of high and low cystatin C.

228 cells (DC) are the predominant producers of cystatin C.

229 established renal function indices eGFR and cystatin C.

230 rmined by longitudinal measurements of serum cystatin C.

231 tory activity or amyloidogenic properties of cystatin C.

232 atinine, cystatin C (eGFRcys) and creatinine-cystatin C.

233 ar filtration rate (GFR), estimated GFR, and cystatin C.

234 to creatinine-based equations compared with cystatin C.

235 for legumain is 100-fold higher than that of cystatin C.

236 terminal pro-B type natriuretic peptide, and cystatin C.

237 ylarginine, high-sensitivity troponin T, and cystatin C.

238 omarkers (haemoglobin, cTn-hs, and GDF-15 or cystatin C/CKD-EPI) was internally and externally valida

239 factors (relative risk: 1.82 per doubling of cystatin C; 95% confidence interval [CI]: 1.56 to 2.13;

240 we evaluate endogenous cathepsin inhibitors cystatins C and B.

241 tive protein, urinary albumin excretion, and cystatin-C had similar risk for new-onset HF between bot

242 ulative urine volume and the change in serum cystatin-C in 72 hours.

243 -treated groups had a 35% reduction in serum cystatin-C levels and reduced crescent numbers compared

244 n factor 15), GAL-3 (galectin-3), and Cys-C (cystatin-C) were assessed before TAVR and in 100 sex-mat

245 y cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and ala

246 nalyzed by levels of serum creatinine, urea, cystatin-C, and urea creatinine.

247 nogen, C-reactive protein, sST2, galectin-3, cystatin-C, and urinary albumin-to-creatinine ratio.

248 sC5b-9) and renal injury markers (clusterin, cystatin-C, beta2-microglobulin, and liver fatty acid bi

249 , galectin-3, midregional proadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others.

250 Except for a modest effect of cystatin-C, no biomarker was associated with increased r

251 We further assessed the impact of using cystatin-C-based eGFR in risk prediction equations for C

252 and international guidelines recommend that cystatin-C-based estimates of GFR be used to confirm or

253 measurement method of renal function such as cystatin-C-derived or directly measured GFR.

254 ctive treatment's effect and EF on change in cystatin-C.

255 proteinuria, and a 6-fold increase in serum cystatin-C.

256 he control group; Chromogranin-A[rs9658644], Cystatin-C[rs2424577] and Vitamin K-Dependent Protein S[

257 However, cystatin clearance, estimated GFR, and hemoglobin levels

258 mily 2 cystatins, including the reproductive cystatin CRES, is an integral structure in the mouse epi

259 sistently, transcriptomic analysis show that cystatin D alters gene expression, including that of gen

260 Strikingly, cystatin D has been found to inhibit proliferation, migr

261 ese results support an unanticipated role of cystatin D in the cell nucleus, controlling the transcri

262 Cystatin D is an inhibitor of lysosomal and secreted cys

263 Here, we demonstrate that a proportion of cystatin D locates within the cell nucleus at specific t

264 hermore, using cytokine arrays we found that cystatin D reduces the secretion of several protumor cyt

265 ied 292 proteins differentially expressed in cystatin D-expressing cells involved in cell adhesion, c

266 op to a rigid beta-strand and by traditional cystatin domain swapping.

267 of the crystalline form but also exposure of cystatin domains for inhibition of cysteine proteases.

268 verse relationship between the expression of cystatin E/M and cathepsin L and a direct relationship b

269 Thus, cystatin E/M appears to be a good candidate to efficient

270 nd a direct relationship between the loss of cystatin E/M expression and nuclear expression of NF-kap

271 cline in drinking water, confirming that the cystatin E/M gene is a tumor suppressor gene.

272 We and others have shown that the cystatin E/M gene is inactivated in primary human tumors

273 Using plasmid-directed cystatin E/M gene overexpression, a lentivirus-mediated

274 or alpha (TNF-alpha), confirming the role of cystatin E/M in the regulation of the NF-kappaB signalin

275 take of cystatin C and the related inhibitor cystatin E/M occur in melanoma cell lines and to evaluat

276 We therefore propose that the cystatin E/M suppressor gene plays an important role in

277 Cystatin E/M was internalized as well but at a modest ra

278 We have demonstrated that cystatin F (CF) is a critical survival factor for eosino

279 ndosomal/lysosomal cathepsin inhibitor named Cystatin F.

280 We show the CRES monomer has a typical cystatin fold that assembles into highly branched amyloi

281 ociated matrisome network, including type II cystatin gene cluster, mucin 5, and cathepsin loci, via

282 Similarly, down-regulating cystatin Icy-2, one of the proteinaceous inhibitors of t

283 nd medical applications of several sugarcane cystatins, including CaneCPI-1, CaneCPI-2, CaneCPI-3, an

284 amyloid matrix composed of several family 2 cystatins, including the reproductive cystatin CRES, is

285 However, human recombinant cystatin is very expensive, and alternatives to its use

286 ts in the industrial process of lysozyme and cystatin isolation from egg white, and (ii) evaluate the

287 , determined at 1.93 A resolution, shows the cystatin-like fold and is highly similar to the structur

288 lecular interaction site on HRG, possesses a cystatin-like fold composed of a 5-stranded antiparallel

289 ray structure of monomeric SQT-1C revealed a cystatin-like fold.

290 be positively affected by engineering of the cystatin molecule.

291 rt the characterization of a novel sugarcane cystatin, named CaneCPI-5.

292 Under conditions that favour fibrillisation, cystatins populate stable 3D domain-swapped dimers both

293 dundant cathepsins, inhibited by Ca074Me and cystatins, promote pro-IL-1beta synthesis, and to our kn

294 The epididymal lumen contains a complex cystatin-rich nonpathological amyloid matrix with putati

295 etic non-antibody capture protein based on a cystatin scaffold that displays high affinity for human

296 Specifically, acidic proline-rich protein, cystatin, statherin and protein S100-A9 proteins compete

297 er-promoting processes might be controled by cystatin uptake.

298 P (gPRPs, aPRPs, statherins/P-B peptide, and cystatins) using HPLC-UV and fluorescence.

299 This cystatin was efficiently expressed in Escherichia coli,

300 e derived from ovalbumin, ovotransferrin and cystatin were isolated from the most active fractions.